Trial Profile
A Phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus para-aortic irradiation for stage III/IV endometrial carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 03 Feb 2021 Status changed from completed to discontinued.
- 07 Sep 2006 New trial record.